The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Sequencing BTK and BCL2 inhibitors in CLL
In this video, Britten Gordon, BS, The Ohio State University, Columbus, OH, briefly discusses the sequencing of BTK inhibitors and BCL2 inhibitors in the treatment of chronic lymphocytic leukemia (CLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in that we really looked at the two main classes of inhibitors with BTK and then BCL2 with venetoclax, and the current paradigm is really which one do you use first. And there’s really no clear data. And actually some data that’s being shown here at iwCLL is showing that it doesn’t really matter which one you use first or second as the patients have similar outcomes in regards to PFS...
So in that we really looked at the two main classes of inhibitors with BTK and then BCL2 with venetoclax, and the current paradigm is really which one do you use first. And there’s really no clear data. And actually some data that’s being shown here at iwCLL is showing that it doesn’t really matter which one you use first or second as the patients have similar outcomes in regards to PFS. But as more data comes out, it might shift as there are some prognostic factors and maybe patients don’t wanna go into the hospital, maybe then they’ll take a BTK inhibitor or if they don’t wanna take a pill for the rest of their life, maybe they’ll take venetoclax.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
